Dr Melinda Tea

Research Fellow

Centre for Cancer Biology

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.


Year Citation
2026 Gardam, B., Gargett, T., Nam, E., Khan, S., Ormsby, R. J., Poonnoose, S. I., . . . Ebert, L. M. (2026). Tumors Located in the Brain Impair the Frequency and Phenotype of Dendritic Cells in Blood and Tumor.. iScience, 29(3), 115160.
DOI Scopus1 WoS1 Europe PMC1
2026 Polara, R., Gliddon, B. L., Ganesan, R., Davies, L. T., Toubia, J., Lenin, S., . . . Robinson, N. (2026). CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 123(13), e2602460123-1-e2602460123-10.
DOI
2026 Gardam, B., Nam, E., Kollis, P. M., Kilyen‐Coles, J., Lenin, S., Gliddon, B. L., . . . Gargett, T. (2026). A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors. Clinical & Translational Immunology, 15(4), 19 pages.
DOI
2025 Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340.
DOI Scopus6 Europe PMC3
2024 Li, M., Bennett, M. K., Toubia, J., Pope, V. S., Tea, M. N., Tamang, S., . . . Pitson, S. M. (2024). An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma. British Journal of Haematology, 204(2), 566-570.
DOI Scopus1 WoS1 Europe PMC1
2024 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20.
DOI Scopus13 WoS11 Europe PMC10
2022 Lewis, A. C., Pope, V. S., Tea, M. N., Li, M., Nwosu, G. O., Nguyen, T. M., . . . Pitson, S. M. (2022). Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.. Blood, 139(26), 3737-3751.
DOI Scopus46 WoS41 Europe PMC45
2022 Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., . . . Gargett, T. (2022). Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. Frontiers in immunology, 13, 850226-1-850226-19.
DOI Scopus24 WoS24 Europe PMC22
2022 Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
DOI Scopus102 WoS101 Europe PMC96
2021 Oksdath Mansilla, M., Salazar-Hernandez, C., Perrin, S. L., Scheer, K. G., Cildir, G., Toubia, J., . . . Gomez, G. A. (2021). 3D-printed microplate inserts for long term high-resolution imaging of live brain organoids. BMC biomedical engineering, 3(6), 1-14.
DOI Europe PMC24
2021 Lenin, S., Ponthier, E., Scheer, K. G., Yeo, E. C. F., Tea, M. N., Ebert, L. M., . . . Gomez, G. A. (2021). A drug screening pipeline using 2D and 3D patient-derived in vitro models for pre-clinical analysis of therapy response in glioblastoma. International Journal of Molecular Sciences, 22(9), 4322-1-4322-27.
DOI Scopus45 WoS42 Europe PMC36
2021 Bennett, M. K., Li, M., Tea, M. N., Pitman, M. R., Toubia, J., Wang, P. P. -S., . . . Pitson, S. M. (2021). Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.. Neoplasia, 24(1), 1-11.
DOI Scopus16 WoS16 Europe PMC14
2020 Tea, M. N., Poonnoose, S. I., & Pitson, S. M. (2020). Targeting the sphingolipid system as a therapeutic direction for glioblastoma. Cancers, 12(1), 111-1-111-25.
DOI Scopus44 WoS44 Europe PMC39
2020 Boyle, S. T., Poltavets, V., Kular, J., Pyne, N. T., Sandow, J. J., Lewis, A. C., . . . Samuel, M. S. (2020). ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism. Nature Cell Biology, 22(7), 882-895.
DOI Scopus62 WoS62 Europe PMC57
2020 Boyle, S. T., Poltavets, V., Kular, J., Pyne, N. T., Sandow, J. J., Lewis, A. C., . . . Samuel, M. S. (2020). Publisher Correction: ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism.. Nat Cell Biol, 22(7), 908.
DOI Scopus5 WoS4 Europe PMC6
2020 Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24.
DOI Scopus63 WoS60 Europe PMC55
2019 Neubauer, H. A., Tea, M. N., Zebol, J. R., Gliddon, B. L., Stefanidis, C., Moretti, P. A. B., . . . Pitson, S. M. (2019). Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. Oncogene, 38(8), 1151-1165.
DOI Scopus27 WoS26 Europe PMC20
2017 Hughes, J., Dawson, R., Tea, M., McAninch, D., Piltz, S., Jackson, D., . . . Thomas, P. (2017). Knockout of the epilepsy gene Depdc5 in mice causes severe embryonic dysmorphology with hyperactivity of mTORC1 signalling. Scientific Reports, 7(1), 12618-1-12618-15.
DOI Scopus51 WoS47 Europe PMC46
2013 Tea, M., Michael, M. Z., Brereton, H. M., & Williams, K. A. (2013). Stability of small non-coding RNA reference gene expression in the rat retina during exposure to cyclic hyperoxia. Molecular vision, 19, 501-508.
Scopus20 WoS18 Europe PMC16
2012 Colella, A., Chegenii, N., Tea, M. N., Gibbins, I., Williams, K., & Chataway, T. (2012). Comparison of Stain-Free gels with traditional immunoblot loading control methodology. Analytical biochemistry, 430(2), 108-110.
DOI Scopus120 WoS120 Europe PMC110
2009 Tea, M., Fogarty, R., Brereton, H., Michael, M., Van der Hoek, M., Tsykin, A., . . . Williams, K. (2009). Gene expression microarray analysis of early oxygen-induced retinopathy in the rat. Journal of Ocular Biology, Diseases, and Informatics, 2(4), 190-201.
DOI Scopus14 Europe PMC10
2008 Irani, Y., Tea, M. N., Tilton, R. G., Coster, D., Williams, K., & Brereton, H. (2008). PCR amplification of the functional immunoglobulin heavy chain variable gene from a hybridoma in the presence of two aberrant transcripts. Journal of Immunological Methods, 336(2), 246-250.
DOI Scopus12 WoS12 Europe PMC9
2007 Brereton, H. M., Chamberlain, D., Yang, R., Tea, M., McNeil, S., Coster, D. J., & Williams, K. A. (2007). Single chain antibody fragments for ocular use produced at high levels in a commercial wheat variety. Journal of Biotechnology, 129(3), 539-546.
DOI Scopus22 Europe PMC14
2005 Brereton, H. M., Taylor, S. D., Farrall, A., Hocking, D., Thiel, M. A., Tea, M., . . . Williams, K. A. (2005). Influence of format on in vitro penetration of antibody fragments through porcine cornea. British Journal of Ophthalmology, 89(9), 1205-1209.
DOI Scopus23 Europe PMC19
2005 Turner, M. L., Cockerell, E. J., Brereton, H. M., Badenoch, P. R., Tea, M., Coster, D. J., & Williams, K. A. (2005). Antigens of selected Acanthamoeba species detected with monoclonal antibodies. International Journal for Parasitology, 35(9), 981-990.
DOI Scopus20 Europe PMC17
  • Overcoming the blood-brain barrier for improved brain tumour therapy, Fay Fuller Foundation, 01/07/2024 - 30/06/2027

  • Understanding therapy-induced glioblastoma evolution to overcome treatment resistance, Neurosurgical Research Foundation, 01/01/2026 - 31/12/2026

  • Examining sphingosine kinase 2 as a therapeutic target in diffuse midline glioma, Neurosurgical Research Foundation, 08/10/2025 - 31/12/2026

  • A new therapeutic approach for glioblastoma, Brain Foundation - Annual Research Awards, 01/01/2025 - 31/12/2025

  • Understanding the biology of treatment resistant brain tumours so that new therapeutic approaches can be developed, Neurosurgical Research Foundation, 04/07/2024 - 31/12/2025

  • Targeting sphingosine kinase 1 as a novel therapeutic strategy in childhood medulloblastoma, Neurosurgical Research Foundation, 01/10/2024 - 30/09/2025

  • Pre-clinical evaluation of sphingosine kinase 2 inhibitors as new glioblastoma therapeutics, Neurosurgical Research Foundation, 01/10/2024 - 30/09/2025

  • Developing clinically relevant models of recurrent glioblastoma, Neurosurgical Research Foundation, 30/08/2021 - 31/08/2022

  • Inhibiting ER-stress induced CD47 to treat Glioblastoma, Neurosurgical Research Foundation, 30/08/2021 - 31/08/2022

  • Stereotactic alignment and injection system for the generation of xenografts of human brain tumours into the brains of mice for pre-clinical testing of new and existing therapeutics, Neurosurgical Research Foundation, 01/01/2018 - 31/12/2018

Date Role Research Topic Program Degree Type Student Load Student Name
2026 Co-Supervisor Targeting Sphingosine kinase 1 in as a therapeutic approach in childhood medulloblastoma Master of Research Master Full Time Mrs Alyssa Ta
2026 Co-Supervisor Discovery and assessment of new therapies for diffuse midline glioma Master of Research Master Full Time Mr Dung Nguyen
2025 Co-Supervisor 535 - Targeting sphingolipid metabolism as a therapy for diffuse midline glioma Doctor of Philosophy Doctorate Full Time Mr Sarmad Khan

Connect With Me

External Profiles

Other Links